| Development of a Physiologically Based Pharmacokinetic Model of Trichloroethylene and Its Metabolites for Use in Risk Assessment Harvey J. Clewell III,1 P. Robinan Gentry,1 Tammie R. Covington,1 and Jeffery M. Gearhart2 1The K.S. Crump Group, Inc., ICF Consulting, Ruston, Louisiana USA; 2Procter & Gamble Company, Cincinnati, Ohio USA Abstract
A physiologically based pharmacokinetic (PBPK) model was developed that provides a comprehensive description of the kinetics of trichloroethylene (TCE) and its metabolites, trichloroethanol (TCOH) , trichloroacetic acid (TCA) , and dichloroacetic acid (DCA) , in the mouse, rat, and human for both oral and inhalation exposure. The model includes descriptions of the three principal target tissues for cancer identified in animal bioassays: liver, lung, and kidney. Cancer dose metrics provided in the model include the area under the concentration curve (AUC) for TCA and DCA in the plasma, the peak concentration and AUC for chloral in the tracheobronchial region of the lung, and the production of a thioacetylating intermediate from dichlorovinylcysteine in the kidney. Additional dose metrics provided for noncancer risk assessment include the peak concentrations and AUCs for TCE and TCOH in the blood, as well as the total metabolism of TCE divided by the body weight. Sensitivity and uncertainty analyses were performed on the model to evaluate its suitability for use in a pharmacokinetic risk assessment for TCE. Model predictions of TCE, TCA, DCA, and TCOH concentrations in rodents and humans are in good agreement with a variety of experimental data, suggesting that the model should provide a useful basis for evaluating cross-species differences in pharmacokinetics for these chemicals. In the case of the lung and kidney target tissues, however, only limited data are available for establishing cross-species pharmacokinetics. As a result, PBPK model calculations of target tissue dose for lung and kidney should be used with caution. Key words: dichloroacetic acid, dichlorovinylcysteine, metabolism, model, PBPK, pharmacokinetics, risk assessment, trichloroacetic acid, trichloroethanol, trichloroethylene. -- Environ Health Perspect 108(suppl 2) :283-305 (2000) . http://ehpnet1.niehs.nih.gov/docs/2000/suppl-2/283-305clewell/abstract.html
The full version of this article is available for free in HTML format. |
